ArticleExpert opinion on therapeutic targets2011
Bitter taste receptors as a target for bronchodilation.
Article in Expert opinion on therapeutic targets, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 19 citations in OpenAlex.
- Acrid and Bitter Chinese Herbs in Decoction Effectively Relieve Lung Inflammation and Regulation of TRPV1/TAS2R14 Channels in a Rat Asthmatic Model.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the present treatments for asthma (β(2)-adrenoceptor agonists, glucocorticoids, leukotriene receptor antagonists), many subjects with asthma have difficulty controlling it. Bitter taste receptors have recently been identified on human lung. The paper evaluated considers these receptors as a target for bronchodilation, by characterizing the effects of agonists in cultured human airway smooth muscle cells, isolated human bronchial smooth muscle and a mouse model of allergic asthma. The study confirmed that a bitter taste receptor (TAS2R) is a viable target for bronchodilation. Many diverse chemicals are known to stimulate the bitter taste receptors to produce the bitter taste, and many of these have more than one mechanism of action. Thus, it is not known whether any of these have clinical potential in asthma. It may be necessary to design and develop selective agonists for TAS2R, before the clinical potential of this target can be thoroughly investigated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.